Stargardt Disease Treatment

Gerard M. Nolan, M.D., F.A.C.S. Nolan Eye & Laser Center

The purpose of this website is to share Dr. Nolan’s 25-year clinical experience treating Stargardt disease using off-label low-dose echothiophate iodide therapy. Dr. Nolan has treated more than 350 patients with Stargardt disease utilizing topical cholinergic modulation therapy (TCM) with echothiophate iodide.

Over years of follow-up, many patients have demonstrated delayed disease progression and/or sustained improvement in visual acuity and color vision. Visual improvement usually begins shortly after the initial application of the medication. Clinical response has been particularly notable in patients with baseline best-corrected visual acuity (BCVA) between 20/200 and 20/400, as well as in patients with BCVA worse than 20/400.

The following publications, manuscripts, and case studies summarize Dr. Nolan’s clinical experience and ongoing research in retinal cholinergic modulation:

• From Clinical Observation to Neurophysiologic Hypothesis: Twenty-Five Years of Retinal Cholinergic Modulation in Stargardt Disease (2026) – A 25-year review tracing the original clinical observation in Patient A260 through subsequent investigations of retinal cholinergic modulation. The article incorporates independent ophthalmologic and electrophysiologic evaluations, recent genetic confirmation of ABCA4-associated Stargardt disease, and subsequent clinical observations that challenge a purely optical or pinhole explanation for the visual response.
• The Successful Management of Stargardt Disease Using Topical Diluted Echothiophate Iodide (2003) – The original manuscript describing Patient A260, a 27-year-old woman with advanced Stargardt disease who demonstrated improvement in visual acuity, near vision, color vision, and functional independence following treatment with dilute topical echothiophate iodide.
• 309-Patient Retrospective Study (Patients A001–A309) – Including a 2005 IRB analysis and four detailed case histories of patients treated between 2001 and 2020.
• 59-Patient Cohort Study: Cholinergic Modulation in Hereditary Retinal Disease (2026) (Patients B001–B059) – An ongoing study of genetically characterized hereditary retinal disease patients treated between June 2022 and June 2026.
• 2025 Four Siblings Case Study – Four consecutive siblings from the prospective cohort (Patients B019, B022, B026, and B032).
• Original 29-Patient Manuscript – Documenting the first clinical observations of retinal cholinergic modulation (1999–2001).
• Aniridia Patient Treatment – A case report demonstrating visual improvement despite the absence of iris-mediated miosis, providing evidence against a purely optical mechanism and supporting investigation of a non-optical mechanism of retinal cholinergic modulation.
• Case Study #1 – First reported treatment case demonstrating marked visual and color-vision recovery (Patient A260).
• Case Studies #2 and #3 (IRB 2005) – First reported monozygotic (identical) twin treatment cases (Patients A061 and A247).
• Case Study #4 (IRB 2005) – Long-term follow-up demonstrating durability of treatment effect over an interval exceeding 10 years (Patient A086).

Dr. Nolan’s goal is to make this treatment protocol available to the greatest number of patients suffering from Stargardt disease. Patients have traveled from throughout the United States and many foreign countries to undergo evaluation and treatment at the Nolan Eye & Laser Center in Farmington, Connecticut. Because multiple visits are often required during the first year of treatment, travel and treatment expenses may create a financial burden for some patients. Dr. Nolan hopes that ophthalmologists throughout the United States and internationally may evaluate and potentially adopt this treatment protocol for appropriate patients locally.

This presentation is for ophthalmologists and eye care professionals only. It is not intended to encourage self-diagnosis or self-treatment of any ocular disease. The purpose of this website is to promote scientific discussion and expand awareness of potential therapeutic approaches for patients under the care of licensed ophthalmologists.

There are no financial conflicts of interest related to this research. No external financial support, grant funding, or industry sponsorship has been received from any individual or organization.